Will you live to 100 with Healtnet?

A roadmap to high-tech medicine. 

This March, the Presidential Council for Modernization and Innovative Economic Development approved HealthNet, a roadmap for the market of personalized medical services and medicines. The strategic goal of the project is to significantly increase the life expectancy through the creation of new effective means of prevention and treatment of various diseases. HealthNet is to become an open ecosystem for developing and supporting producers of biotech and medical products and services.

1. Information technologies in medicine
2. Medical genetics
3. Biomedicine
4. Sport and health
5. Preventive medicine 6. Healthy longevity.



By 2035, HealthNet should drastically change the country’s medical system. Many things which seem fantastic today will become routine: 3D organ printing, “smart” cyber prosthetics, individual approach to treating diseases based on the particularities of the patient’s DNA, correction of potentially dangerous pathologies at the cellular level staring from birth, “active aging“ — a comprehensive life extension program, thanks to which you will physically feel like a 20-year-old even at 80, and much, much more.

The comprehensive development of all areas should substantially improve the living standards of the population. Theoretically, the domestic economy should also benefit. For example, due to a potential increase in the retirement age (after all, active life will last longer), the Pension Fund’s and the Mandatory Medical Insurance Fund’s costs will be significantly reduced.


The main economic effect is expected from the fact that the development of the HealthNet program will allow domestic companies to grow and become leaders in the new high-tech markets which will shape the structure of the world’s economy for the next 15-20 years and, possibly, will enable Russia to join the group of innovative leaders.

Many experts believe that Russia has a potential for such growth. First of all, there is the high research potential of the Russian medicine based on breakthrough discoveries of the Soviet era; Russia holds leadership positions in the development of world-class application software, database organization and the use of BigData technologies necessary for personalized medical services.

The HealthNet Roadmap should be implemented in three phases. The first phase (2017-2019) envisages the creation of the infrastructure necessary for the development of small companies for the market: they will maintain the flow of high-tech solutions and will serve as the foundation for the emergence of the global high-tech HealthNet market.


At the first stage, there will be identification, selection and support not only for technology companies and start-ups, but also for promising research and development projects.

According to the Agency for Strategic Initiatives and the Russian Venture Company, currently 10 out of 137 projects have been selected, and at least 5 projects will be submitted for examination by the interdepartmental working group before the end of the year, including 2 projects planned for release in September. As a result, the authors of projects aimed at overcoming existing technological barriers or pursuing research in top- priority technologies should receive funding.

Evgeny Kovnir, Deputy Director, Young Professionals Division, AGENCY FOR STRATEGIC INITIATIVES 

We help the companies participating in the HealthNet market to overcome the regulatory barriers, we examine their projects, we provide the most relevant analytics concerning the development of the industry. In addition, they get an opportunity to obtain further acceleration from such innovation centers as Skolkovo. In particular, the founders of the largest start-up accelerator in Eastern Europe, GenerationS, have established a special nomination in the field of medical services and medicines. The best project will be reviewed by the HealthNet working group for the inclusion in the roadmap, will receive comprehensive infrastructural, administrative and financial support.

In addition, we are currently preparing for the selection of applications for the UMNIK-NTI contest to be held by the Foundation for the Promotion of Innovation. The contest is aimed at supporting commercially oriented scientific and technical projects of young researchers aged from 18 to 35. This year, fifty grants, 500,000 rubles each, have been specifically awarded for the development of scientific projects within HealthNet. We expect to receive at least 100 applications, and to complete the selection and identify the best initiatives in November.

Annually, based on the results of competitions and other support measures, the so-called “companies of hope” — companies with the potential for rapid growth — will be identified.

Already, experts have identified a promising company called Atlas which is engaged in genome sequencing, i.e. creating a special test that can find genetic damage (mutation) in the DNA responsible for hereditary diseases or dangerous predispositions in both adults and newborns, as well as the one called Semantic Hub, which specializes in the adaptation and standardization of the medical language.

Igor Korobko, Director of the Department of Science, Innovation Development and Management of Biomedical Health Risks, MINISTRY OF HEALTH OF RUSSIA 

A comprehensive infrastructure was created in the Tomsk region for the full cycle of clinical trials of medicines and medical products on the basis of the Siberian State Medical University as part of the Translational Medicine Consortium. The development of translational medicine will make it possible to quickly turn scientific developments into products and services that will not only improve the efficiency of public health services, but also contribute to the implementation of the strategy of advanced import substitution.

It is expected that by 2020 the mechanism for supporting small innovative companies will be fully streamlined, and the number of those companies will constantly grow.

The second phase of the HealthNet Roadmap (2020- 2025) involves the creation and development of infrastructure to support medium-sized companies in the HealthNet market: updating the regulatory framework in connection with the emergence of new technologies and new approaches identified during phase one; implementing the concept of changing the education system; involving government institutions of international cooperation to support the entry of HealthNet companies into international markets; and implementing medium-term market projects to create an enabling environment for companies identified as having priority during phase one.

And the third phase (2026-2035) will involve the implementation of long-term projects, including the replication of technological solutions through the development of companies, and the full launch of projects, whose pilot stages were implemented during the first and second phases.

Igor Korobko:

As a result of the implementation of the HealthNet Roadmap, by 2035 five Russian companies working in the HealthNet market segments should be among the

world’s top 70 companies in this market by sales volume, and 70% of products and services should have a full production cycle in Russia. By the volume of consumption of HealthNet market products per capita, Russia should be among the world’s top 20 countries.



According to preliminary estimates, the volume of the global HealthNet market within the global health market will reach $2 trillion by 2020 and over $9 trillion by 2035. At the same time, by 2035, the Russian share of the HealthNet market will be at least 3% of the global volume.

In monetary terms, the total effect from the implementation of the measures laid down in the roadmap will amount to almost 4 trillion rubles by 2035, including the economic effect in the form of improved health indicators of almost 2 trillion rubles, the commercial effect of just over one trillion rubles, and the attracted investments of 738 billion rubles.

Those responsible for the development of the HealthNet market and other innovative markets of the National Technology Initiative will help Russia not only to cope with such important economic tasks as the development of innovations, import substitution, and the creation of an enabling environment for the development of high-tech small companies, but also to become one of the world’s technological leaders. At the expert session of the Coordinating Club of the Free Economic Society of Russia prominent Russian economists assessed potential obstacles to these plans.

  • The share of Russian companies will increase from 7.8% TO 57%
  • The number of high-tech Russian companies will grow from 4 TO 21 THOUSAND
  • The number of international patents issued will increase to 11.4 THOUSAND
  • The target number of companies with a capitalization of more than $5 million is 408


Author: Evgenia Mamonova 


Пожалуйста, введите ваш комментарий!
пожалуйста, введите ваше имя здесь